Jersey Medical Cannabis Posts First Profit on £12m Revenue

Jersey’s medical cannabis industry posted its first operating profit in 2025, generating £12 million in revenue against more than £47 million in cumulative capital investment, according to the island government’s Future Economy Programme Delivery Update. The sector employs 70 people and exported nearly 6,800 kilograms of dried cannabis flower last year — roughly triple the prior year’s volume.

For a jurisdiction that issued its first commercial cultivation licences in December 2020, the profit milestone is real. But the underlying economics have a structural gap: Jersey is exporting bulk raw material while the higher-margin downstream steps — processing, packaging, finished-product release — take place, and generate revenue, somewhere else.

Inside the Numbers

Government freedom-of-information data shows 6,786 kilograms of dried cannabis flower shipped from Jersey in 2025, with exports to Great Britain and Northern Ireland growing 348% from 2024. The island also exported cannabis oil in smaller volumes. The rise reflects the expansion of Jersey’s EU-GMP certified production base alongside demand growth across British and European medical markets.

The volume growth is heavily concentrated. Northern Leaf, the island’s largest licensed producer, accounts for an estimated 90% of current production. Its 100,000-square-foot facility in St Lawrence — EU-GMP certified and the largest on the island — supplied 3,590 kilograms to Germany in 2025, according to export data obtained by Prohibition Partners via freedom-of-information requests, making Northern Leaf the largest UK-based exporter of medical cannabis flower to that market. The company, which faced serious financial difficulty in early 2025, has since rebuilt its production significantly.

Scale context matters. Industry data puts Canada’s share of UK medical cannabis imports at roughly 57%. Continental producers in Malta and North Macedonia operate at volumes Jersey cannot match. The island’s competitive argument has never been scale — it’s been speed and regulatory agility. Jersey’s export permit turnaround is among the fastest in the global industry, and its geography — a two-hour ferry crossing to France — allows road shipments to reach Germany in under 36 hours.

Bulk Flower, Downstream Margin

Dried flower dominates what Jersey ships, and it’s leaving in bulk form: active pharmaceutical ingredient, the raw input before any of the clinical-grade processing, dosing, labelling, and patient-facing product release that transforms it into a finished medicine for pharmacy dispensing.

The finishing steps are where the margin accumulates. Finished, pharmacy-ready product commands substantially more per kilogram than the bulk flower it’s made from. While Jersey’s licensed producers have crossed into profitable territory, the revenue figure reflects only part of the economic value that leaves the island with each shipment.

Two producers are technically positioned to move beyond bulk. Green Island Growers and Caprica — both locally owned — have achieved GMP Part One certification, the standard that permits manufacture and release of finished medicinal products. Caprica received that certification from the UK’s medicines regulator in October 2025. As European clinical programs and finished-product supply chains continue to develop across the continent, the companies had every reason to expect those certifications would translate into production authority.

They haven’t yet. In April 2026, Jersey’s government confirmed it could not issue the manufacturing licences needed to activate those certifications. Health and Care Jersey said a review found the existing licensing system insufficient, and that work had begun on improvements. The regulatory infrastructure for medicines manufacturing hadn’t been built to a standard that allowed licences to be granted — months after the certifications were awarded and companies had begun investing against them. Green Island Growers’ chief executive told the Jersey Evening Post the situation was “a little bit crazy,” with the opportunity present and producers ready to act but the government unable to issue the required licences.

The Compounding Risk

Jersey’s structural advantages haven’t gone away. The island has some of the cheapest and cleanest electricity in Europe, better suited to controlled indoor cultivation than the greenhouse production that dominates sunnier competing jurisdictions. Its regulators have shown a willingness to move at commercial speed. An amendment to the island’s proceeds-of-crime framework in 2021 allows cannabis income from regulated recreational markets in roughly 30 jurisdictions to flow through Jersey without being treated as criminal proceeds — a meaningful signal for international businesses assessing European market entry.

Those advantages matter most if Jersey’s producers are capturing the full value chain. If the manufacturing licence framework doesn’t materialise, the commercial logic gradually shifts: outsource finishing work to third-party facilities in Portugal, the Netherlands, or Germany; operate Jersey as a raw-material supplier; and leave the downstream margin with whoever does the finishing. As global medical cannabis operators compete for vertically integrated supply positions, that’s a structural retreat the island’s industry would struggle to reverse.

The first profit is a legitimate operational milestone. Whether the regulatory infrastructure catches up fast enough to preserve Jersey’s position in the value chain above bulk flower is a different question — and one that 2026 is already starting to answer.